Ad26.RSV.preF
Phase 2Biologic
Johnson & JohnsonAd26.RSV.preF is one of 30 biologic programs targeting Respiratory Syncytial Virus Infection. It is currently in Phase 2.
2
Indications
7
Total Trials
0
Active Trials
29
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1053 competitors in Influenza
#DrugCompanyPhaseTrials
1Fluzone
SanofiPreclinical
Fluzone
GSKPreclinical
Trexall
Alnylam PharmaceuticalsPreclinical
Crestor
AstraZenecaPreclinical
Avigan
AAppili Therapeutics Inc.
Preclinical
Quadrivalent Influenza Vaccine
SanofiPreclinical
Ad26.RSV.preF
Johnson & JohnsonPhase 2
COMIRNATY
PfizerPreclinical
Influenza A/H5N1
NNational Institute of Allergy and Infectious Diseases (NIAID)
Preclinical
Fluvirin
NovartisPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Immunogenicity3 trials
Respiratory Syncytial Virus2 trials
Influenza1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Ad26.RSV.preF. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 2[1]
- Company